Greater body mass independently predicts less radiographic progression on X-ray and MRI over 1–2 years

Development and Validation of Modified Disease Activity Scores in Rheumatoid Arthritis: Superior Correlation With Magnetic Resonance Imaging-Detected Synovitis and Radiographic Progression

(2013) Joshua F. Baker et al.   Arthritis & Rheumatology

Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: A long-term followup from disease onset

(2012) Sofia Ajeganova et al.   ARTHRITIS CARE & RESEARCH

Anti-sclerostin antibody and mechanical loading appear to influence metaphyseal bone independently in rats

(2011) Fredrik Agholme et al.   Acta Orthopaedica

Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial

(2011) P. G. Conaghan et al.   ANNALS OF THE RHEUMATIC DISEASES

Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis

(2011) J. T. Giles et al.   ANNALS OF THE RHEUMATIC DISEASES

Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints

(2011) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered

(2011) A. Moustafa et al.   OSTEOPOROSIS INTERNATIONAL

Associations between body mass, radiographic joint damage, adipokines and risk factors for bone loss in rheumatoid arthritis

(2011) J. F. Baker et al.   RHEUMATOLOGY

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study

(2010) E. Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind, randomized study

(2010) Paul Emery et al.   ARTHRITIS AND RHEUMATISM

Golimumab, a new human anti-tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

(2010) Joel Kremer et al.   ARTHRITIS AND RHEUMATISM

Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months

(2010) Inga-Lill Engvall et al.   ARTHRITIS RESEARCH & THERAPY

Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis

(2009) Jon T. Giles et al.   ARTHRITIS AND RHEUMATISM

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

(2009) Paul Emery et al.   ARTHRITIS AND RHEUMATISM

Golimumab, a human antibody to tumour necrosis factor   given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

(2008) E C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)

(2008) M L Hetland et al.   ANNALS OF THE RHEUMATIC DISEASES

A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis

(2007) A H M van der Helm-van Mil et al.   ANNALS OF THE RHEUMATIC DISEASES